Abstract
The atypical PKC isoforms (ζ and ı) play essential roles in regulating various cellular processes. Both the hetero-interaction between PKCζ and p62 through their N-terminal PB1 domains and the homo-oligomerization of p62 via its PB1 domain are critical for the activation of NF-κB signaling; however, the molecular mechanisms concerning the formation and regulation of these homotypic complexes remain unclear. Here we determined the crystal structure of PKCζ-PB1 in complex with a monomeric p62-PB1 mutant, where the massive electrostatic interactions between the acidic OPCA motif of PKCζ-PB1 and the basic surface of p62-PB1, as well as additional hydrogen bonds, ensure the formation of a stable and specific complex. The PKCζ-p62 interaction is interfered with the modification of a specific Cys of PKCζ by the antiarthritis drug aurothiomalate, though all four cysteine residues in the PKCζ-PB1 domain can be modified in in vitro assay. In addition, detailed structural and biochemical analyses demonstrate that the PB1 domains of aPKCs belong to the type I group, which can depolymerize the high-molecular-weight p62 aggregates into homo-oligomers of lower order. These data together unravel the molecular mechanisms of the homo-or hetero-interactions between p62 and PKCζ and provide the basis for designing inhibitors of NF-κB signaling.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev, 2008, 88: 1341–1378
Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. Protein kinase C intervention—the state of play. Curr Opin Cell Biol, 2009, 21: 268–279
Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov, 2012, 11: 937–957
Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev, 2001, 101: 2353–2364
Hirai T, Chida K. Protein kinase Cξ (PKCξ): activation mechanisms and cellular functions. J J Biochem, 2003, 133: 1–7
Suzuki A, Akimoto K, Ohno S. Protein kinase C λ/ı (PKCλ/ı): a PKC isotype essential for the development of multicellular organisms. J Biochem, 2003, 133: 9–16
Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science, 2003, 300: 445–452
Sumimoto H, Kamakura S, Ito T. Structure and function of the PB1 domain, a protein interaction module conserved in animals, fungi, amoebas, and plants. Sci STKE, 2007, 2007: re6
Moscat J, Diaz-Meco MT. The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters. EMBO Rep, 2000, 1: 399–403
Moscat J, Diaz-Meco MT, Albert A, Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol Cell, 2006, 23: 631–640
Puls A, Schmidt S, Grawe F, Stabel S. Interaction of protein kinase C ξ with ZIP, a novel protein kinase C-binding protein. Proc Natl Acad Sci USA, 1997, 94: 6191–6196
Sanchez P, De Carcer G, Sandoval IV, Moscat J, Diaz-Meco MT. Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62. Mol Cell Biol, 1998, 18: 3069–3080
Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell, 2009, 137: 1001–1004
Moscat J, Diaz-Meco MT. p62: a versatile multitasker takes on cancer. Trends Biochem Sci, 2012, 37: 230–236
Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-κB activation. EMBO J, 1999, 18: 3044–3053
Sanz L, Diaz-Meco MT, Nakano H, Moscat J. The atypical PKC-interacting protein p62 channels NF-κB activation by the IL-1-TRAF6 pathway. EMBO J, 2000, 19: 1576–1586
Diaz-Meco M, Moscat J. The atypical PKCs in inflammation: NF-κB and beyond. Immunol Rev, 2012, 246: 154–167
Lamark T, Perander M, Outzen H, Kristiansen K, Øvervatn A, Michaelsen E, Bjørkøy G, Johansen T. Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. J Biol Chem, 2003, 278: 34568–34581
Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Øvervatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol, 2005, 171: 603–614
Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT, Moscat J. The p62 scaffold regulates nerve growth factor-induced NF-κB activation by influencing TRAF6 polyubiquitination. J Biol Chem, 2005, 280: 35625–35629
Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, Moscat J. The signaling adaptor p62 is an important NF-κB mediator in tumorigenesis. Cancer Cell, 2008, 13: 343–354
Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol, 1997, 276: 307–326
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr, 2007, 40: 658–674
Hirano Y, Yoshinaga S, Takeya R, Suzuki NN, Horiuchi M, Kohjima M, Sumimoto H, Inagaki F. Structure of a cell polarity regulator, a complex between atypical PKC and Par6 PB1 domains. J Biol Chem, 2005, 280: 9653–9661
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr, 2010, 66: 213–221
Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr, 2010, 66: 486–501
Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr, 1993, 26: 283–291
Dynon MK, Jago GR, Davidson BE, Gething MJH. The subunit structure of lactate dehydrogenase from Streptococcus cremoris US3. Eur J Biochem, 1972, 30: 348–353
Yoshinaga S, Kohjima M, Ogura K, Yokochi M, Takeya R, Ito T, Sumimoto H, Inagaki F. The PB1 domain and the PC motif-containing region are structurally similar protein binding modules. EMBO J, 2003, 22: 4888–4897
Hu Q, Shen W, Huang H, Liu J, Zhang J, Huang X, Wu J, Shi Y. Insight into the binding properties of MEKK3 PB1 to MEK5 PB1 from its solution structure. Biochemistry, 2007, 46: 13478–13489
Noda Y, Kohjima M, Izaki T, Ota K, Yoshinaga S, Inagaki F, Ito T, Sumimoto H. Molecular recognition in dimerization between PB1 domains. J Biol Chem, 2003, 278: 43516–43524
Wilson MI, Gill DJ, Perisic O, Quinn MT, Williams RL. PB1 domain-mediated heterodimerization in NADPH oxidase and signaling complexes of atypical protein kinase C with Par6 and p62. Mol Cell, 2003, 12: 39–50
Saio T, Yokochi M, Inagaki F. The NMR structure of the p62 PB1 domain, a key protein in autophagy and NF-κB signaling pathway. J Biomol NMR, 2009, 45: 335–341
Saio T, Yokochi M, Kumeta H, Inagaki F. PCS-based structure determination of protein-protein complexes. J Biomol NMR, 2010, 46: 271–280
Hirano Y, Yoshinaga S, Ogura K, Yokochi M, Noda Y, Sumimoto H, Inagaki F. Solution structure of atypical protein kinase C PB1 domain and its mode of interaction with ZIP/p62 and MEK5. J Biol Chem, 2004, 279: 31883–31890
Terasawa H, Noda Y, Ito T, Hatanaka H, Ichikawa S, Ogura K, Sumimoto H, Inagaki F. Structure and ligand recognition of the PB1 domain: a novel protein module binding to the PC motif. EMBO J, 2001, 20: 3947–3956
Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol, 2000, 164: 5981–5989
Erdogan E, Lamark T, Stallings-Mann M, Jamieson L, Pellechia M, Thompson EA, Johansen T, Fields AP. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cı. J Biol Chem, 2006, 281: 28450–28459
Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Cı blocks transformed growth of non-small-cell lung cancer cells. Cancer Res, 2006, 66: 1767–1774
Fields AP, Regala RP. Protein kinase Cı: Human oncogene, prognostic marker and therapeutic target. Pharmacol Res, 2007, 55: 487–497
Gunatilleke S, de Oliveira C, McCammon J, Barrios A. Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. J Biol Inorg Chem, 2008, 13: 555–561
Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum, 2010, 62: 1650–1659
Sakurai A, Yuasa K, Shoji Y, Himeno S, Tsujimoto M, Kunimoto M, Imura N, Hara S. Overexpression of thioredoxin reductase 1 regulates NF-κB activation. J Cell Physiol, 2004, 198: 22–30
Trani M, Sorrentino A, Busch C, Landström M. Pro-apoptotic effect of aurothiomalate in prostate cancer cells. Cell Cycle, 2009, 8: 306–313
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at link.springer.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Ren, J., Wang, J., Wang, Z. et al. Structural and biochemical insights into the homotypic PB1-PB1 complex between PKCζ and p62. Sci. China Life Sci. 57, 69–80 (2014). https://doi.org/10.1007/s11427-013-4592-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4592-z